Molecular dynamics of a biophysical model for β2-adrenergic and G protein-coupled receptor activation

被引:28
作者
Rubenstein, Lester A.
Zauhar, Randy J.
Lanzara, Richard G.
机构
[1] Bio Balance Inc, Pharmacol, New York, NY 10024 USA
[2] Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA
[3] Univ Sci Philadelphia, Dept Chem & Biochem, Philadelphia, PA 19104 USA
关键词
molecular dynamics; two-state model; G protein-coupled receptor model; B2AR adrenergic receptor; sulfhydryl; electrostatic molecular switch; receptor activation;
D O I
10.1016/j.jmgm.2006.02.008
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This study analyzes 16 molecular dynamic simulations of a biophysical model for beta(2)-adrenergic (beta 2AR) and G protein-coupled receptor (GPCR) activation. In this model, a highly conserved cysteine residue, C106 (C3.25 or CysIII:01), provides a free sulfhydryl or thiol group in an acid-base equilibrium between uncharged (RSH) and charged (RS-) states that functions as an electrostatic molecular switch for receptor activation. The transition of C106 in the B2AR between acid and base states significantly changes the helical/transmembrane (TM) domain interactions and the electrostatic interaction energy differences (Delta Delta E-EL). The Delta Delta E-EL changes correlate well with the experimentally observed ligand efficacies. The TM interaction energies display patterns compatible with those previously recognized as responsible for GPCR activation. Key differences between the agonist, epinephrine, and the antagonist, pindolol, are seen for the TM3 x 6, TM3 x 4, TM6 x 7 and TM1 x 7 interaction energies. Pindolol also produces a weaker Delta Delta E-EL interaction and less TM interaction energy changes, which are important differences between the agonist and antagonist ligands. The D115E mutant with pindolol displays a greater Delta Delta E-EL and TM interactions than for the wild-type B2AR with pindolol. This explains the higher activity of pindolol in the D115E mutant. The constitutively active D130A mutant displays TM interaction patterns similar to those for the activating ligands implying a common pattern for receptor activation. These findings support the broad concept of protean agonism and demonstrate the potential for allosteric modulation. They also demonstrate that this two-state model agrees with many previous experimental and theoretical observations of GPCRs. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:396 / 409
页数:14
相关论文
共 52 条
[1]  
[Anonymous], INT J PHARM
[2]   An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors [J].
Baldwin, JM ;
Schertler, GFX ;
Unger, VM .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 272 (01) :144-164
[3]   Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6 [J].
Ballesteros, JA ;
Jensen, AD ;
Liapakis, G ;
Rasmussen, SGF ;
Shi, L ;
Gether, U ;
Javitch, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) :29171-29177
[4]  
Ballesteros JA, 1995, Methods Neurosci, V25, P366, DOI [DOI 10.1016/S1043-9471(05)80049-7, 10.1016/S1043-9471(05)80049-7]
[5]   PHYSIOLOGICAL-EFFECTS OF INVERSE AGONISTS IN TRANSGENIC MICE WITH MYOCARDIAL OVEREXPRESSION OF THE BETA(2)-ADRENOCEPTOR [J].
BOND, RA ;
LEFF, P ;
JOHNSON, TD ;
MILANO, CA ;
ROCKMAN, HA ;
MCMINN, TR ;
APPARSUNDARAM, S ;
HYEK, MF ;
KENAKIN, TP ;
ALLEN, LF ;
LEFKOWITZ, RJ .
NATURE, 1995, 374 (6519) :272-276
[6]  
CERIONE RA, 1986, J BIOL CHEM, V261, P3901
[7]   THE MAMMALIAN BETA-2-ADRENERGIC RECEPTOR - RECONSTITUTION OF FUNCTIONAL INTERACTIONS BETWEEN PURE RECEPTOR AND PURE STIMULATORY NUCLEOTIDE BINDING-PROTEIN OF THE ADENYLATE-CYCLASE SYSTEM [J].
CERIONE, RA ;
CODINA, J ;
BENOVIC, JL ;
LEFKOWITZ, RJ ;
BIRNBAUMER, L ;
CARON, MG .
BIOCHEMISTRY, 1984, 23 (20) :4519-4525
[8]   G protein-coupled receptor allosterism and complexing [J].
Christopoulos, A ;
Kenakin, T .
PHARMACOLOGICAL REVIEWS, 2002, 54 (02) :323-374
[9]  
Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215
[10]  
Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924